Ultragenyx Pharmaceutical reported $6.1M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 2.95M 0.39M
Alnylam Pharmaceuticals ALNY:US $ 35.63M 2.04M
Biocryst Pharmaceuticals BCRX:US $ 0.24M 0.18M
Biomarin Pharmaceutical BMRN:US $ 116.96M 2.78M
Epizyme EPZM:US $ 2.64M 516K
Esperion Therapeutics ESPR:US $ 7.12M 2.05M
Insmed INSM:US $ 12.19M 1.1M
IONIS PHARMACEUT IONS:US $ 4.17M 1.94M
Karyopharm Therapeutics KPTI:US $ 1.43M 684K
Kyowa Hakko Kirin 4151:JP Y 22159M 1582M
MacroGenics MGNX:US 48K 899K
Moderna Inc MRNA:US 1.02B 65M
Neurocrine Biosciences NBIX:US $ 4.6M 0.5M
Ptc Therapeutics PTCT:US $ 10.14M 0.81M
Puma Biotechnology PBYI:US $ 10.84M 1.05M
Regeneron Pharmaceuticals REGN:US $ 404.9M 577.7M
Sarepta Therapeutics SRPT:US $ 31.44M 0.3M
Ultragenyx Pharmaceutical RARE:US $ 6.1M 2.59M
Vertex Pharmaceuticals VRTX:US $ 245.8M 1.59M